

SYMATESE

THE SCIENCE OF TISSUE REGENERATION & RECONSTRUCTION,
AND ITS ADMINISTRATION SYSTEMS FOR THE BENEFIT OF DOCTORS AND PATIENTS.

Press Release

Bornel, near Paris, France, May 11, 2026

ESTYME® INJECTABLE HYALURONIC ACID GELS
NOW COMMERCIALY AVAILABLE IN EUROPE
THROUGH THE SYMATESE-EVOLUS PARTNERSHIP

SYMATESE Group, a leading expert in hyaluronic acid, today announced that its partner Evolus Inc. will launch Estyme®, its injectable hyaluronic acid (HA) gel collection in Europe, on May 16th, marking the entry of SYMATESE into the European dermal filler market.

The Estyme® collection includes four injectable HA gels that will cover a wide range of applications: Estyme® Smooth and Estyme® Form, which are currently marketed in the United States under the brand Evolysse®, along with the debut of two products including Estyme® Sculpt, which is expecting U.S. FDA approval later this year and Estyme® Lips.

Developed for restoring mid-face volume, Estyme® Sculpt addresses one of the most in-demand treatment areas in aesthetics. Designed by SYMATESE, the innovative COLD-X® Technology by SYMATESE helps preserve the natural structure of the HA molecule, providing long-lasting, natural-looking results.

The commercial launch follows the successful CE Mark certification under the European Medical Device Regulation (MDR) which was obtained by SYMATESE and represents one of the most stringent regulatory frameworks globally, validating the safety, efficacy, and quality of the Estyme® collection.

“We are proud to partner with Evolus in bringing the Estyme® collection of injectable HA gels to Europe — building on the successful launches of Evolysse® in the U.S. in April 2025 and Estyme® in France in May 2025” said Jean-Paul Gérardin, Chief Executive Officer of SYMATESE. “With decades of experience in biomaterial science in aesthetics and in therapeutical domains, SYMATESE has a strong legacy of developing innovative aesthetic products that meet the evolving needs of practitioners and their patients. With one of the largest clinical trial programs undertaken for an injectable HA technology, Estyme® products are being evaluated for safety and effectiveness in over 2,400 patients globally”.

SYMATESe

THE SCIENCE OF TISSUE REGENERATION & RECONSTRUCTION,
AND ITS ADMINISTRATION SYSTEMS FOR THE BENEFIT OF DOCTORS AND PATIENTS.

About SYMATESE

With 27 years of existence, SYMATESE has established itself as a leading expert in the science of tissue regeneration. Thanks to cutting-edge research and its technological platform integrating collagen, hyaluronic acid, silicones and thermoplastics, the company develops innovative medical solutions that transform patients' lives and revolutionize practices in some fifteen medical specialties. Drawing on its expertise in therapeutic areas, we have made significant advances in aesthetic medicine. Agreements have been reached with renowned partners to access global coverage, in particular with Evolus Inc., thanks to the collaborations established in May and December 2023 respectively for the USA and Europe, while Evolus' neurotoxin, Nuceiva® and Estyme® dermal fillers are commercialized in France by a subsidiary of SYMATESE. These agreements are part of SYMATESE Transform Plan 2025-2029, marked in 2024 by the launch on the American market of Lacrifill® for the treatment of dry eye with our partner Nordic Pharma, followed by the commercialization in Brazil, by our Brazilian subsidiary, of the Estyme® Matrix range of breast implants, based on Pryme® Technology by SYMATESE. With its continued commitment to research and development, SYMATESE is accelerating its global rollout in 2026 already initiated in 2024 and is well positioned to continue shaping the future of regenerative and aesthetic medicine. Visit us at <http://www.symatесе.com>, and follow us on [LinkedIn](#).

Nuceiva® and Evolysse® are registered trademarks of Evolus, Inc.

Estyme® and COLD-X® are registered trademarks of SYMATESE AESTHETICS S.A.S and SYMATESE Group.

SYMATESE Contact:

Laurent BRONES – +33 6 14 31 13 57